{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:40:35Z","timestamp":1761946835345,"version":"3.44.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008038","name":"Herman Frasch Foundation for Chemical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.bcp.2019.113668","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T19:46:01Z","timestamp":1571255161000},"page":"113668","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["A luciferase lysis assay reveals in vivo malignant cell sensitization by phosphoantigen prodrugs"],"prefix":"10.1016","volume":"170","author":[{"given":"Jin","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas A.","family":"Lentini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David F.","family":"Wiemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Wiemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.bcp.2019.113668_b0005","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nri.2017.101","article-title":"\u03b3\u03b4 T cells in homeostasis and host defence of epithelial barrier tissues","volume":"17","author":"Nielsen","year":"2017","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2019.113668_b0010","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1146\/annurev-immunol-032713-120216","article-title":"\u03b3\u03b4 T cells: first line of defense and beyond","volume":"32","author":"Chien","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bcp.2019.113668_b0015","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.semcdb.2017.10.009","article-title":"\u03b3\u03b4 T cell responses: how many ligands will it take till we know?","volume":"84","author":"Vermijlen","year":"2018","journal-title":"Semin. Cell Dev. Biol."},{"issue":"8","key":"10.1016\/j.bcp.2019.113668_b0020","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.4049\/jimmunol.175.8.5471","article-title":"In vivo immunomanipulation of V\u03b39V\u03b42 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model","volume":"175","author":"Sicard","year":"2005","journal-title":"J. Immunol."},{"issue":"6527","key":"10.1016\/j.bcp.2019.113668_b0025","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/375155a0","article-title":"Natural and synthetic non-peptide antigens recognized by human \u03b3\u03b4 T cells","volume":"375","author":"Tanaka","year":"1995","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bcp.2019.113668_b0030","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/1074-7613(95)90178-7","article-title":"Direct presentation of nonpeptide prenyl pyrophosphate antigens to human \u03b3\u03b4 T cells","volume":"3","author":"Morita","year":"1995","journal-title":"Immunity"},{"issue":"2\u20133","key":"10.1016\/j.bcp.2019.113668_b0035","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-3083.2007.01963.x","article-title":"Lysis of a broad range of epithelial tumour cells by human \u03b3\u03b4 T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition","volume":"66","author":"Wrobel","year":"2007","journal-title":"Scand. J. Immunol."},{"issue":"13","key":"10.1016\/j.bcp.2019.113668_b0040","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93179","article-title":"Adoptively transferred V\u03b39V\u03b42 T cells show potent antitumor effects in a preclinical B cell lymphomagenesis model","volume":"2","author":"Zumwalde","year":"2017","journal-title":"JCI Insight"},{"issue":"8","key":"10.1016\/j.bcp.2019.113668_b0045","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.chembiol.2014.06.006","article-title":"Synthesis of a phosphoantigen prodrug that potently activates V\u03b39V\u03b42 T-lymphocytes","volume":"21","author":"Hsiao","year":"2014","journal-title":"Chem. Biol."},{"issue":"18","key":"10.1016\/j.bcp.2019.113668_b0050","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.2174\/156802610793176602","article-title":"Isoprenoid metabolism as a therapeutic target in gram-negative pathogens","volume":"10","author":"Wiemer","year":"2010","journal-title":"Curr. Top. Med. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2019.113668_b0055","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1124\/mol.105.020776","article-title":"Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis","volume":"69","author":"Thompson","year":"2006","journal-title":"Mol. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2019.113668_b0060","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/bcp.13855","article-title":"Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo-controlled, phase I study in healthy volunteers","volume":"85","author":"Gan","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2019.113668_b0065","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1021\/acsmedchemlett.7b00245","article-title":"Mixed aryl phosphonate prodrugs of a butyrophilin ligand","volume":"8","author":"Foust","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.bcp.2019.113668_b0070","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1021\/acs.jmedchem.6b00965","article-title":"Phosphinophosphonates and their tris-pivaloyloxymethyl prodrugs reveal a negatively cooperative butyrophilin activation mechanism","volume":"60","author":"Shippy","year":"2017","journal-title":"J. Med. Chem."},{"issue":"19","key":"10.1016\/j.bcp.2019.113668_b0075","doi-asserted-by":"crossref","first-page":"8658","DOI":"10.1021\/acs.jmedchem.8b00655","article-title":"Phosphonamidate prodrugs of a butyrophilin ligand display plasma stability and potent V\u03b39 V\u03b42 T cell stimulation","volume":"61","author":"Lentini","year":"2018","journal-title":"J. Med. Chem."},{"issue":"17","key":"10.1016\/j.bcp.2019.113668_b0080","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/cmdc.201900344","article-title":"Stability and efficiency of mixed aryl phosphonate prodrugs","volume":"14","author":"Foust","year":"2019","journal-title":"ChemMedChem"},{"issue":"14","key":"10.1016\/j.bcp.2019.113668_b0085","doi-asserted-by":"crossref","first-page":"6814","DOI":"10.1021\/acs.jmedchem.9b00825","article-title":"Probing the ligand-binding pocket of BTN3A1","volume":"62","author":"Poe","year":"2019","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.bcp.2019.113668_b0090","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1021\/acsmedchemlett.9b00153","article-title":"Synthesis and bioactivity of the alanyl phosphonamidate stereoisomers derived from a butyrophilin ligand","volume":"10","author":"Lentini","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"issue":"2","key":"10.1016\/j.bcp.2019.113668_b0095","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4049\/jimmunol.1501833","article-title":"HMBPP analog prodrugs bypass energy-dependent uptake to promote efficient BTN3A1-mediated malignant cell lysis by V\u03b39V\u03b42 T lymphocyte effectors","volume":"197","author":"Kilcollins","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2019.113668_b0100","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1600-065X.2006.00479.x","article-title":"Nonpeptide antigens, presentation mechanisms, and immunological memory of human V\u03b32V\u03b42 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens","volume":"215","author":"Morita","year":"2007","journal-title":"Immunol. Rev."},{"issue":"828","key":"10.1016\/j.bcp.2019.113668_b0105","doi-asserted-by":"crossref","first-page":"828","DOI":"10.3389\/fimmu.2018.00828","article-title":"Towards deciphering the hidden mechanisms that contribute to the antigenic activation process of human V\u03b39V\u03b42 T cells","volume":"9","author":"Boutin","year":"2018","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.bcp.2019.113668_b0110","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1002\/eji.201444712","article-title":"V\u03b39V\u03b42 TCR-activation by phosphorylated antigens requires butyrophilin 3 A1 (BTN3A1) and additional genes on human chromosome 6","volume":"44","author":"Riano","year":"2014","journal-title":"Eur. J. Immunol."},{"issue":"11","key":"10.1016\/j.bcp.2019.113668_b0115","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2012-05-430470","article-title":"Key implication of CD277\/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human \u03b3\u03b4 T-cell subset","volume":"120","author":"Harly","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bcp.2019.113668_b0120","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.immuni.2014.03.003","article-title":"The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human V\u03b39V\u03b42 T cells","volume":"40","author":"Sandstrom","year":"2014","journal-title":"Immunity"},{"issue":"35","key":"10.1016\/j.bcp.2019.113668_b0125","doi-asserted-by":"crossref","first-page":"E7311","DOI":"10.1073\/pnas.1707547114","article-title":"Phosphoantigen-induced conformational change of butyrophilin 3A1 (BTN3A1) and its implication on V\u03b39V\u03b42 T cell activation","volume":"114","author":"Gu","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"11","key":"10.1016\/j.bcp.2019.113668_b0130","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1096\/fj.201601370RR","article-title":"The butyrophilin 3A1 intracellular domain undergoes a conformational change involving the juxtamembrane region","volume":"31","author":"Nguyen","year":"2017","journal-title":"FASEB J."},{"issue":"4","key":"10.1016\/j.bcp.2019.113668_b0135","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.immuni.2019.02.016","article-title":"A structural change in butyrophilin upon phosphoantigen binding underlies phosphoantigen-mediated V\u03b39V\u03b42 T Cell activation","volume":"50","author":"Yang","year":"2019","journal-title":"Immunity"},{"issue":"1\u20132","key":"10.1016\/j.bcp.2019.113668_b0140","first-page":"43","article-title":"Fas-mediated cytotoxicity by \u03b3\u03b4 T cells during acute rejection in xenotransplantation of spheroidal aggregate-cultured hepatocytes","volume":"105","author":"Ota","year":"1999","journal-title":"Res. Commun. Mol. Pathol. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2019.113668_b0145","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/(SICI)1096-9896(199712)183:4<432::AID-PATH942>3.0.CO;2-4","article-title":"Cytotoxic protein expression in natural killer cell lymphomas and in \u03b1\u03b2 and \u03b3\u03b4 peripheral T-cell lymphomas","volume":"183","author":"Boulland","year":"1997","journal-title":"J. Pathol."},{"issue":"3","key":"10.1016\/j.bcp.2019.113668_b0150","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.4049\/jimmunol.161.3.1558","article-title":"Involvement of the Fas\/Fas ligand pathway in activation-induced cell death of mycobacteria-reactive human \u03b3\u03b4 T cells: a mechanism for the loss of \u03b3\u03b4 T cells in patients with pulmonary tuberculosis","volume":"161","author":"Li","year":"1998","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.bcp.2019.113668_b0155","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.immuni.2009.08.006","article-title":"\u03b3\u03b4 T cells and the lymphoid stress-surveillance response","volume":"31","author":"Hayday","year":"2009","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.bcp.2019.113668_b0160","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nri3384","article-title":"Six-of-the-best: unique contributions of \u03b3\u03b4 T cells to immunology","volume":"13","author":"Vantourout","year":"2013","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.bcp.2019.113668_b0165","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.tibs.2017.11.008","article-title":"Mechanisms of initiation and propagation","volume":"43","author":"Courtney","year":"2018","journal-title":"Trends Biochem. Sci."},{"issue":"7","key":"10.1016\/j.bcp.2019.113668_b0170","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.4049\/jimmunol.1100103","article-title":"A live imaging cell motility screen identifies prostaglandin E2 as a T cell stop signal antagonist","volume":"187","author":"Wiemer","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2019.113668_b0175","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.bcp.2018.10.035","article-title":"A power law function describes the time- and dose-dependency of V\u03b39V\u03b42 T cell activation by phosphoantigens","volume":"158","author":"Hsiao","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2019.113668_b0180","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41598-017-18606-1","article-title":"Development and characterization of a novel luciferase based cytotoxicity assay","volume":"8","author":"Matta","year":"2018","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.bcp.2019.113668_b0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089357","article-title":"Measuring cytotoxicity by bioluminescence imaging outperforms the standard chromium-51 release assay","volume":"9","author":"Karimi","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.bcp.2019.113668_b0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011867","article-title":"A simple and sensitive method for measuring tumor-specific T cell cytotoxicity","volume":"5","author":"Fu","year":"2010","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.bcp.2019.113668_b0195","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1084\/jem.20110226","article-title":"The aminobisphosphonate pamidronate controls influenza pathogenesis by expanding a \u03b3\u03b4 T cell population in humanized mice","volume":"208","author":"Tu","year":"2011","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.bcp.2019.113668_b0200","first-page":"181","article-title":"Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs","volume":"14","author":"Brunner","year":"1968","journal-title":"Immunology"},{"key":"10.1016\/j.bcp.2019.113668_b0205","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jim.2019.01.003","article-title":"Determination of human \u03b3\u03b4 T cell-mediated cytotoxicity using a non-radioactive assay system","volume":"466","author":"Tagod","year":"2019","journal-title":"J. Immunol. Methods"},{"issue":"2","key":"10.1016\/j.bcp.2019.113668_b0210","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1216291","article-title":"Zoledronic acid boosts \u03b3\u03b4 T-cell activity in children receiving \u03b1\u03b2(+) T and CD19(+) cell-depleted grafts from an HLA-haplo-identical donor","volume":"6","author":"Bertaina","year":"2017","journal-title":"Oncoimmunology"},{"issue":"8","key":"10.1016\/j.bcp.2019.113668_b0215","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.exphem.2009.04.008","article-title":"Clinical and immunological evaluation of zoledronate-activated V\u03b39\u03b3\u03b4 T-cell-based immunotherapy for patients with multiple myeloma","volume":"37","author":"Abe","year":"2009","journal-title":"Exp. Hematol."},{"issue":"13","key":"10.1016\/j.bcp.2019.113668_b0220","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1158\/0008-5472.CAN-10-3862","article-title":"High phosphoantigen levels in bisphosphonate-treated human breast tumors promote V\u03b39V\u03b42 T-cell chemotaxis and cytotoxicity in vivo","volume":"71","author":"Benzaid","year":"2011","journal-title":"Cancer Res."},{"issue":"22","key":"10.1016\/j.bcp.2019.113668_b0225","doi-asserted-by":"crossref","first-page":"6249","DOI":"10.1158\/1078-0432.CCR-12-0918","article-title":"In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger V\u03b39V\u03b42 T-cell antitumor cytotoxicity through ICAM-1 engagement","volume":"18","author":"Benzaid","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2019.113668_b0230","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/cmi.2012.46","article-title":"Multifunctional immune responses of HMBPP-specific V\u03b32V\u03b42 T cells in M. tuberculosis and other infections","volume":"10","author":"Chen","year":"2013","journal-title":"Cell. Mol. Immunol."},{"issue":"43","key":"10.1016\/j.bcp.2019.113668_b0235","doi-asserted-by":"crossref","DOI":"10.1088\/0957-4484\/22\/43\/435101","article-title":"The use of myristic acid as a ligand of polyethylenimine\/DNA nanoparticles for targeted gene therapy of glioblastoma","volume":"22","author":"Li","year":"2011","journal-title":"Nanotechnology"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219303673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219303673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:07:07Z","timestamp":1757768827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295219303673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":47,"alternative-id":["S0006295219303673"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2019.113668","relation":{},"ISSN":["0006-2952"],"issn-type":[{"type":"print","value":"0006-2952"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A luciferase lysis assay reveals in vivo malignant cell sensitization by phosphoantigen prodrugs","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2019.113668","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113668"}}